Human settlement in England
POPULARITY
37 episodes with Kidderminster
12 episodes with Kidderminster
5 episodes with Kidderminster
13 episodes with Kidderminster
6 episodes with Kidderminster
2 episodes with Kidderminster
3 episodes with Kidderminster
2 episodes with Kidderminster
2 episodes with Kidderminster
We discuss a resolute 1-0 victory over play off chasing Hereford, which secured second place and home advantage in the play offs following Kidderminster's unexpected slip up at Southport. We also look ahead to Saturday's play off semi final against Chorley, following their narrow victory over King's Lynn on Tuesday. Hosted on Acast. See acast.com/privacy for more information.
Aaron Paul & Jobi McAnuff are joined by Phil Brown as Leeds & Burnley are promoted to the Premier League. Hear from Chris Wilder as Sheffield United have to settle for a play-off place. Luton boss Matt Bloomfield joins the pod with his team inside the relegation zone on goal difference. There are twists and turns at the top of League One and League Two. And will goalkeepers be given a break in 72PLUS 72MINUS?02:05 Phil's Kidderminster title race goes to final day 06:05 Leeds and Burnley promoted to the Premier League 16:10 Sheff Utd have to settle for the play-offs 21:15 WBA, Norwich & Cardiff sack their managers 23:05 Luton boss Matt Bloomfield joins the pod 31:40 Can Charlton gatecrash the League One automatics? 34:30 Doncaster jump to top of League Two 37:30 Jobi's best & worst moments in 72PLUS 72MINUSBBC Sounds / 5 Live / Radio 5 Sports Extra weekend commentaries: Sat 1500 Newcastle v Ipswich in the Premier League, Sat 1715 Crystal Palace v Aston Villa in the FA Cup semis, Sun 1400 Bournemouth v Man Utd in the Premier League, Sun 1400 Chelsea v Barcelona in the Women's Champions League, Sun 1630 Liverpool v Tottenham in the Premier League, Sun 1630 Nottingham Forest v Man City in the FA Cup semis.
This week Gaz & Jordan are joined by former Histon, Wrexham, Peterborough, Shrewsbury, Bradford, Carlisle, Morecambe, Tranmere, Kidderminster, Tamworth & Southport defender...Nathaniel Knight-Percival!Nathaniel sits down with the boys to discuss all things football from playing as a winger for Histon to then transitioning to a centre half and playing in the Championship.The lads then chat about his experience of playing in non-league before a big move to Wrexham which saw him having to man mark Dean Saunders in his office, facing up against Jamie Vardy & Gaz in the league before a HUGE move to the Championship came about.Nathaniel and the boys then discuss how his Peterborough deal came about and how difficult it was to step up 3 leagues, Why people don't realise the brilliance of Lee Tomlin and who were his toughest opponents.Nathaniel then talks about who the best and worst managers he's played under are, reuniting with Micky Mellon and the heart break of losing in the play-off final.The trio then discuss Nathaniel's issues with Chris Beech, why Jarrad Branthwaite was always destined for greatness and finally how they won promotion with Morecambe despite being relegation favourites.Support the show
Sutton United's winning run continues! In this episode of Sutton United Talk Time on Podcast, we dive into the team's post-Christmas resurgence, their FA Trophy triumph over Kidderminster, and the growing confidence within the squad. Are we finally seeing the full potential of this team?Episode Overview:Host Mike is joined by Julian and Dan as they break down Sutton's recent performances, the defensive improvements, and what's making the squad tick. With the FA Trophy win secured and another big fixture on the horizon, the trio discuss the team's chemistry, tactical flexibility, and how key players are stepping up. Can Sutton keep this momentum going?Notable Quotes:"They all enjoy playing together anyway. They seem that way. They seem to get on and are forging great partnerships." – Julian"When it's dagger time, we need to be ruthless and put the game to bed." – DanGuest Information:Julian and Dan bring their insight and passion to the discussion, analysing Sutton United's evolving form and what it means for upcoming matches.Call to Action:Enjoyed this episode? Don't forget to like, comment, and subscribe! Share your thoughts on Sutton's performance and follow us for more match reactions and analysis. Hosted on Acast. See acast.com/privacy for more information.
Luke Edwards is joined by the holy trinity of Christian, Dickie and Joe as York start 2025 leading the way but Ryan Innis's goal for Forest Green keeps the heat on at the top. It's as you were at the bottom as only Woking really make any progress. In the North a big win for the Iron, Kidderminster's ''After the Lord Mayors Show and Marine score away for the time since August In the South Joe tells us about the Devon/Cornwall derby, Weston having a mare and can St Albans pull off the great escape? Learn more about your ad choices. Visit podcastchoices.com/adchoices
Morse code transcription: vvv vvv Thomas Plimmer Woman says struck off sex GP tried to choke her Selena Gomez announces engagement to Benny Blanco Storm Darragh not a storm, Kidderminster man told by insurers Rural Kent on the frontline of PMs housebuilding battle 20mph Which Welsh roads have seen most offences Ofgem She died because of me five words that changed the Sara Sharif trial XL bully Baby seriously injured in dog attack in Folkestone Bowel cancer rates rising among younger people Shopkeeper tracks down mum stealing Jellycat toys to sell on Vinted
Morse code transcription: vvv vvv She died because of me five words that changed the Sara Sharif trial Ofgem Storm Darragh not a storm, Kidderminster man told by insurers 20mph Which Welsh roads have seen most offences Shopkeeper tracks down mum stealing Jellycat toys to sell on Vinted Selena Gomez announces engagement to Benny Blanco XL bully Baby seriously injured in dog attack in Folkestone Thomas Plimmer Woman says struck off sex GP tried to choke her Bowel cancer rates rising among younger people Rural Kent on the frontline of PMs housebuilding battle
Morse code transcription: vvv vvv 20mph Which Welsh roads have seen most offences She died because of me five words that changed the Sara Sharif trial Storm Darragh not a storm, Kidderminster man told by insurers Shopkeeper tracks down mum stealing Jellycat toys to sell on Vinted XL bully Baby seriously injured in dog attack in Folkestone Thomas Plimmer Woman says struck off sex GP tried to choke her Ofgem Rural Kent on the frontline of PMs housebuilding battle Bowel cancer rates rising among younger people Selena Gomez announces engagement to Benny Blanco
Morse code transcription: vvv vvv Shopkeeper tracks down mum stealing Jellycat toys to sell on Vinted Bowel cancer rates rising among younger people Rural Kent on the frontline of PMs housebuilding battle XL bully Baby seriously injured in dog attack in Folkestone Storm Darragh not a storm, Kidderminster man told by insurers Thomas Plimmer Woman says struck off sex GP tried to choke her Ofgem Selena Gomez announces engagement to Benny Blanco She died because of me five words that changed the Sara Sharif trial 20mph Which Welsh roads have seen most offences
On this week's episode Martin is whisking us up to Worcestershire in England's West Midlands and telling us his take on the legend of "The Malvern Ogre."We start off chatting about what Martin calls 'a proper saint' - his namesake, St Martin - including his life as a goose-bothering wandering necromancer and the strange part-bloody, part-weather related traditions associated with today's festival of Martinmas. After that we set off for Worcestershire, a sometimes overlooked county with extraordinarily rich history and folklore to be found in just about every corner.We discuss topics including the very frequently-destroyed County Town of Worcester, the county's plethora of standing stones and its fractious past, then Martin grabs up his bottle of Worcestershire Sauce and chats through the county's extremely rich culinary heritage, and its offal-centred ancient delicacy, Tenbury Pie, for this week's County Dish.As for folklore, interspersed with some excerpts from next Saturday's Local Legends interview with Worcestershire local, folklorist and author Hugh Williams, we talk about the county's resident centaur, its fairies, black dog legend, a spontaneously combusting witch from Kidderminster, and much more besides.Then it's on to the main event: Martin's story, "The Malvern Ogre" which, in a change of pace from recent weeks, is a jolly tale about people-eating monsters, personal hygiene, and the magical power of kindness.We hope you enjoy it, and will be back on Thursday with a new Three Ravens Bestiary bonus episode about Nymphs and, if you're a Patreon supporter, our November Patreon Exclusive episode about The Medway Megaliths, all ahead of Saturday's full Local Legends chat with Hugh!The Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays (Magic and Medicines about folk remedies and arcane spells, Three Ravens Bestiary about cryptids and mythical creatures, Dying Arts about endangered heritage crafts, and Something Wicked about folkloric true crime from across history) plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?Learn more at www.threeravenspodcast.com, join our Patreon at www.patreon.com/threeravenspodcast, and find links to our social media channels here: https://linktr.ee/threeravenspodcast Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.
Aaron Paul and Jobi McAnuff talk EFL with Jed Wallace & Phil Brown. They pay tribute to former Sheffield United defender George Baldock, Championship joint-top scorer Josh Maja joins his West Brom teammate Jed on the pod, and Wimbledon boss Johnnie Jackson comes on after his side was drawn away to MK in the FA Cup. Phil's Kidderminster don't make it into the hat, and it's goals galore in 72plus 72minus.Timecodes: 02:58 George Baldock tributes 07:53 Championship chat 17:44 Josh Maja joins the pod 25:54 Johnnie Jackson talks FA Cup 32:11 Phil Brown opens up about managerial disciplineBBC Sounds / 5 Live commentaries this week:Saturday 19th October Manchester United v Brentford - Premier League - 5 Live from 15:00 Bournemouth v Arsenal - Premier League- 5 Live from 17:30Sunday 20th October Wolves v Man City - Premier League - 5 Live from 14:00 Liverpool v Chelsea - Premier League - 5 Live from 16:30
Kidderminster 0-1 Guiseley AFC, Mark Bower — Edit by Guiseley Radio
Kidderminster 0-1 Guiseley, Joe Cracknell — Edit by Guiseley Radio
We were joined by Crewe captain Mickey Demetriou as he takes us through his non league, letter writing, days, to his time in Spain at the Glenn Hoddle academy. Then back to England and from Kidderminster, Shrewsbury and Newport to his home now in South Cheshire.We discuss last season, why it went well, and what went wrong before moving into this season.We end by looking at what comes next for Mickey. Hosted on Acast. See acast.com/privacy for more information.
This time Nick and Andy are together in the studio. They discuss a recent visit to the Watercress Line (Mid Hants Heritage Railway). The podcast leads on to the wider discussion on the popularity of heritage steam and diesel railways in the UK including the Great Central Railway in Loughborough & The Severn Valley Railway in Kidderminster. There is a big reliance on volunteers. Nick and Andy discuss the advantages (and sometimes) disadvantages to organisations in having a volunteer base.Plus... they ask what sort of people go to heritage railways and what are their expectations of a day out? At the end they sample some Hampshire cheese and talk... as Waitrose fancily term it "terroir".It's all here... get in touch with the podcast via our website: twovoices.co.uk
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Gospel Preaching in Kidderminster, June 20th. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 6/20/2024 Bible: Luke 16 Length: 34 min.
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Gospel Preaching in Kidderminster, June 20th. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 6/20/2024 Bible: Luke 16 Length: 34 min.
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Gospel Preaching in Kidderminster, June 20th. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 6/20/2024 Bible: Luke 16 Length: 34 min.
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Gospel Preaching in Kidderminster, June 20th. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 6/20/2024 Bible: Luke 16 Length: 34 min.
History is a lie agreed upon, and so is the present day when navigating the narratives of the internet's conspiracy crowd. But luckily we have a swathe of talking heads who are here to separate the wheat from the chaff, sift through the bullshit and amplify the white in the white noise. They are here to tell us the truth, no matter how unpalatable, bigoted and fallacious this might seem to reasonable or informed people. In the USA they have entire networks dedicated to distributing this modern day two minutes of hate. It can be highly lucrative to wind up the credulous and furious, and these outlets namely The Daily Wire, OAN, Rebel TV, Turning Point and others do very well and have directed more people to the right wing than a stewardess during a crash landing. These outlets can loosely be described as purveyors of news, in the same way that a dirty protest can loosely be described as an example of elegant home decoration. In the UK we have the propaganda Network GB News and Talk TV. They are very much the Robbie Williams to America's Justin Timberlake in this regard, the Jim Davidson to their Dave Chappelle or the Scunthorpe united to their Dallas Cowboys. Essentially they do the same thing but with wildly different standards of aesthetics and with far less talent, charisma, skill and panache. The main through-line is a mixture of right wing and far right politics and performative outrage deployed through the lens of conspiracy and faux anti government sentiment. But, as I believe Shakespeare once said, there are levels to this shit. If we think of Alex Jones and David Icke as top billing prize fighters slugging it out against the illuminati on a pay per view from Las Vegas, then people like Russel Brand, Laurence Fox and their ilk are a man killing rats with a hammer in a ring of hay-bales in the dimly lit back room of an abandoned warehouse in Kidderminster.
In this episode, we recount the tragic story of Louise Evans, a woman who appeared to have the perfect life in Kidderminster. Married to her childhood sweetheart and mother to three young daughters, Louise's world was shattered in July 2012. Join us as we uncover the dark secrets behind her untimely death, the investigation that followed, and the shocking truth that emerged.Follow Midlands Murder Files on Instagram @MidlandsMurderFiles
In this special publication-day episode, Will and Steve are recording live at Fourbears Books for the launch of Will's latest book, UPSTAIRS AT THE BERESFORD, where they will be talking about what should be the most exciting part of the process and how it has changed from when they started.There are questions from the live audience as well as the usual probing insights from Kidderminster's very own Sandra. Hosted on Acast. See acast.com/privacy for more information.
Rob and Joe review the latest action and are joined by TNT's touchline reporter for the National League, Jeff Brazier, The two Adam's Virgo and Summerton also make an appearance giving their National League memories. Dorking's relegation was confirmed this week and Marc White gives his views and they also celebrate Yeovil's promotion, frown over Brown's Kidderminster and look at an exciting relegation battle in the National League North Subscribe wherever you get your podcasts and leave us a review Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Rob and Joe review the latest action and are joined by TNT's touchline reporter for the National League, Jeff Brazier, The two Adam's Virgo and Summerton also make an appearance giving their National League memories. Dorking's relegation was confirmed this week and Marc White gives his views and they also celebrate Yeovil's promotion, frown over Brown's Kidderminster and look at an exciting relegation battle in the National League NorthSubscribe wherever you get your podcasts and leave us a review Hosted on Acast. See acast.com/privacy for more information.
Rob, Dickie and Joe survey the scene after another action packed National League weekend. It's Chesterfield popping the champagne corks as they get the job done and secure their pathway back to the EFL. Joe watched the battle down at the bottom as Wealdstone drew with Kidderminster, he catches up with the Stones's Marcus Dewhurst and Max Kretzschmar. Plus the rest of the round up from the rest of the National League and also the North and South. Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Rob, Dickie and Joe survey the scene after another action packed National League weekend. It's Chesterfield popping the champagne corks as they get the job done and secure their pathway back to the EFL. Joe watched the battle down at the bottom as Wealdstone drew with Kidderminster, he catches up with the Stones's Marcus Dewhurst and Max Kretzschmar. Plus the rest of the round up from the rest of the National League and also the North and South.Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information.
Music lovers Ali in Kidderminster and Vicky in Manchester take on Ten To The Top
Rob Worrall is joined by Joe Pope and Luke Walsh to look back at 40 goals across just the top division of the National League alone! Chesterfield remain 20 points clear despite a rare defeat, Alty are gunned down by the Shots, Halifax move into the playoff mix whilst Ebbsfleet and Kidderminster who pick up vital points for survival. Plenty of action in the North and South with stalemates at the top of the North and the Glovers keep a hand on the title race, we hear from their assistant manager Chris Todd. Subscribe via all good podcasting platforms and leave a review Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Rob Worrall is joined by Joe Pope and Luke Walsh to look back at 40 goals across just the top division of the National League alone! Chesterfield remain 20 points clear despite a rare defeat, Alty are gunned down by the Shots, Halifax move into the playoff mix whilst Ebbsfleet and Kidderminster who pick up vital points for survival.Plenty of action in the North and South with stalemates at the top of the North and the Glovers keep a hand on the title race, we hear from their assistant manager Chris Todd. Subscribe via all good podcasting platforms and leave a review Hosted on Acast. See acast.com/privacy for more information.
Rob, Joe and Dickie look back at the action from the weekend including the National League Clubs involvement in the Third Round of the FA Cup. Corne does the job from the penalty spot as Maidstone progress past League One Stevenage. Chesterfield are oh so close before getting stung by Watford and Eastleigh take a draw at Newport whilst Aldershot bow out at the Baggies. Plus Brennan's blood boiling at Barnet, Oldham coming up on the rails and Kidderminster running out of steam? And a round up of the National League North and South results Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Rob, Joe and Dickie look back at the action from the weekend including the National League Clubs involvement in the Third Round of the FA Cup.Corne does the job from the penalty spot as Maidstone progress past League One Stevenage. Chesterfield are oh so close before getting stung by Watford and Eastleigh take a draw at Newport whilst Aldershot bow out at the Baggies.Plus Brennan's blood boiling at Barnet, Oldham coming up on the rails and Kidderminster running out of steam?And a round up of the National League North and South resultsSubscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information.
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Kidderminster: Wars and Pestilences. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 1/4/2024 Bible: Matthew 24 Length: 45 min.
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Kidderminster: Wars and Pestilences. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 1/4/2024 Bible: Matthew 24 Length: 45 min.
S5E50 On the edge of Kidderminster lies Hurcott Pool and Wood Nature Reserve. An old boathouse on the edge of the pool has been repurposed by Worcestershire Bat Group and a few minutes away lies Lea Castle Village where the street lighting has been designed with bats at the forefront of its design. We join bat group members Cody Levine and Matthew Terry on a summer evening at the end of July. Watch a video of the boathouse on YouTubeDiscover more about Worcestershire Bat Group and follow them on twitter, facebook and InstagramTake a look at the Wyre Forest page on Hurcott.Read about the Lea Castle Village and how Worcestershire County Council are rolling out red street lighting across the county. Discover your local bat groupThank you to Wildlife Acoustics for sponsoring the BatChat podcast in 2023-2024.Visit wildlifeacoustics.com to learn more. Bat to the Future instalment 5…Johann Natterer. A new feature for Series 5, Bat to the Future will delve into the history of the guys who have bats named after them. With each new episode release, this audio will be replaced with the next instalment so be sure to listen before the next episode comes out!Support the showPlease leave us a review or star rating if your podcast app allows it because it helps us to reach a wider audience so that we can spread the word about how great bats are. How to write a podcast review (and why you should).Got a story to share with us? Please get in touch via comms@bats.org.ukBats are magical but misunderstood. At BCT our vision is a world rich in wildlife where bats and people thrive together. Action to protect & conserve bats is having a positive impact on bat populations in the UK. We would not be able to continue our work to protect bats & their habitats without your contribution so if you can please donate. We need your support now more than ever: www.bats.org.uk/donate Thank you!
A new MP3 sermon from Dr David C. Mackereth is now available on SermonAudio with the following details: Title: Kidderminster: Slow Going. Subtitle: Open Air Gospel Speaker: Dr. David Mackereth Broadcaster: Dr David C. Mackereth Event: Special Meeting Date: 12/12/2023 Length: 34 min.
This week's guest is the LBC radio host, James O'Brien. James grew up in Kidderminster in the 70s and 80s with his adoptive parents Joan and Jim O'Brien. He attended Ampleforth College, the famous Catholic public school in Yorkshire. He describes his school years as rebellious – but reflects that the ‘weird burning sense of injustice' he felt was ‘pretty well placed'. Following in his father's footsteps – James pursued a career in journalism – and got his foot in the door thanks to a chance encounter with John Major. Although he started out in print, he later segued into broadcast – starting his LBC show in 2004. In this episode he discusses with host Kelly-Anne Taylor the impossibility of impartiality, receiving hate on social media, imposter syndrome, his new book 'How They Broke Britain' and what he gets up to on Christmas Day. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Luke Edwards is in the hotseat this week with Joe and Dickie from another action packed week. Can anyone ''Just Stop Oli'' as his double helps Chesterfield extend their lead at the top. Joe sees Aldershot continue their good run at home to Halifax, Dickie gives his thoughts on Kidderminster's survival hopes and he also sees National League North leaders Tamworth in action and speaks with manager Andy Peaks. Plus a round up of all the other games across the three divisions Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Luke Edwards is in the hotseat this week with Joe and Dickie from another action packed week. Can anyone ''Just Stop Oli'' as his double helps Chesterfield extend their lead at the top. Joe sees Aldershot continue their good run at home to Halifax, Dickie gives his thoughts on Kidderminster's survival hopes and he also sees National League North leaders Tamworth in action and speaks with manager Andy Peaks. Plus a round up of all the other games across the three divisions Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information.
Some techie gremlins means a late release and shorter show but plenty to delight, entertain and inform. First up Russ Penn manager at Kidderminster Harriers. From play-off winners last term to rock bottom of the National League this, but there's still hope and still expectation that the small margins can be pushed in the right direction at Aggborough. Matt Badcock is back with his insight into the week's news and previews of the content for this weekend's Non League paper.
This week we get a little more serious and talk about failure. Weirdly, Steve has a lot more to discuss...How do we fail? Why do we fail? Is it always a way to learn? Can writing save us?All of these questions will be answered along with more probing insights by Sandra from Kidderminster. We also try recording remotely, rather than in the snazzy Soho podcast studio.There is also a discussion about Murakami but it went on too long and was edited out. Get involved with the discussion by finding us on Twitter/X @GetLitPodcast. Hosted on Acast. See acast.com/privacy for more information.
From movie deals and foreign rights to awards and reviews, this week we talk about the worst emotion: jealousy.Is everybody else really doing as well as it seems or is it just social media bluster?Can we ever be happy for the success of others?And what happens when you get a bunch of writers in the same room?We also discuss getting paid and doing things for free.And Sandra from Kidderminster is back with one of her probing questions. Hosted on Acast. See acast.com/privacy for more information.
S'mae... Dych chi'n gwrando ar Pigion - podlediad wythnosol Radio Cymru i'r rhai sy'n dysgu ac sydd wedi dysgu Cymraeg. Trystan ab Ifan dw i ac i ddechrau'r wythnos yma … Pigion Dysgwyr – Dechrau‘r Steddfod Buodd Radio Cymru‘n darlledu o Faes yr Eisteddfod ym Moduan drwy'r wythnos diwetha gan ddechrau am ganol dydd ar y dydd Sadwrn cyntaf. Dyma sut dechreuodd y darlledu…… Darlledu To broadcast Cynnau tan To light a fire Cynnal To maintain Blodeuo To flower Eisteddfodwr o fri A renowned Eisteddfod person Hawlio To claim Deuawd Duet Craith A scar Llwyfan Stage Noddi To sponsor Pigion Dysgwyr – Martin Croydon …ac wrth gwrs bydd blas ar sawl darllediad o'r Eisteddfod yn y podlediad wythnos yma, gan ddechrau gyda Martyn Croydon enillodd wobr Dysgwr y Flwyddyn yn yr Eisteddfod Genedlaethol ddeg mlynedd yn ôl. Daw Martin o Kidderminster yn wreiddiol, ond erbyn hyn mae o'n byw ym Mhen Llŷn. Gwobr Prize Enwebu To nominate Rowndiau terfynol Final rounds Gwrthod To refuse Cyfweliad Interview Beirniaid Judges Cynifer So many Cyfathrebu To communicate Ysbrydoli To inspire Cynulleidfa Audience Terfynol Final Pigion Dysgwyr – Dysgwr y Flwyddyn Ac roedd Martyn yn un o'r criw fuodd yn brysur iawn yn cynnal gweithgareddau Maes D yn Steddfod Boduan. Ond pwy enillodd gwobr Dysgwr y Flwyddyn eleni tybed? Roedd pedwar ymgeisydd ardderchog wedi cyrraedd y rownd terfynol, a dydd Mercher yn yr Eisteddfod cyhoeddwyd mai Alison Cairns yw Dysgwr y Flwyddyn eleni. Daw Alison yn wreiddiol o'r Alban ond mae hi a'i theulu erbyn hyn yn byw yn Llannerchymedd ar Ynys Môn. Dyma hi'n sgwrsio ar Post Prynhawn yn dilyn y seremoni wobrwyo. Y gymuned The community Pigion Dysgwyr – Esyllt Nest Roberts de Lewis A llongyfarchiadau i Alison ar ennill y wobr – dwi'n siŵr bydd hi'n mwynhau ei blwyddyn. Daw Esyllt Nest Roberts de Lewis yn wreiddiol o Bencaenewydd ger Pwllheli ond mae hi erbyn hyn yn byw yn ardal Gymraeg Patagonia, sef Y Wladfa, ac wedi bod yno ers nifer o flynyddoedd. Ar Dros Frecwast yr wythnos diwetha cafodd Kate Crocket gyfle i'w holi hi gan ofyn iddi'n gynta iddi pam aeth hi allan i'r Wladfa yn y lle cynta? Yn y cyfamser In the meantime Annerch To address (a meeting) Y cyfryngau The media Dylanwadu To influence Rhyngrwyd Internet Yn anymwybodol Unaware Pigion Dysgwyr – Cai Erith Ac Esyllt oedd yn arwain Cymru a'r Byd, sef y Cymry sy'n byw ym mhob rhan o'r byd erbyn hyn, yn yr Eisteddfod Genedlaethol eleni Os chwiliwch chi ar BBC Sounds gwelwch raglen arbennig wnaeth Aled Hughes ei recordio dan y teitl Mordaith. Rhaglen yw hi lle mae Aled yn hwylio o amgylch Penrhyn Llŷn yn sgwrsio gyda rhai o drigolion yr ardal. Morwr yw Cai Erith a dyma fe'n sôn ychydig am ei fywyd Penrhyn Peninsula Trigolion Residents Porthladdoedd Ports Yn llythrennol Literally Wedi dy hudo di Has lured you Pigion Dysgwyr - Ffobia Hanes bywyd diddorol Cai Erith yn fanna ar raglen Mordaith. Buodd Catrin Mai yn siarad ag Emma Walford a Trystan Ellis Morris ar eu rhaglen yn ddiweddar. Mae gan Catrin ffobia anarferol iawn… sbyngau, neu sponges! Dyma Emma yn holi Catrin gynta……. Cyffwrdd To touch Colur Makeup Fatha Yr un fath â Trin To treat Nadroedd Snakes Corynnod Pryfed cop Arnofio To float Amsugno To absorb
Rob and Joe visit the Wembley Arch to see an epic Play off final between Chesterfield and Notts County, with build up to the final with both sets of fans, in game reaction plus post match reaction from the key people from both sides. Dickie visits Brackley to see Kidderminster gain promotion from the North and he catches up with key figures from the Harriers. Ryan Matthews from the NLS wrap gives us his thoughts on the South final as Oxford City see off St Albans with Joe giving us his summing up. Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Three big games remain at the top of the non league league season. The finals for the National league, national League South and National league north play-offs, to see who takes those remaining promotion spots to climb further up the pyramid. We speak this week with one manager who if he achieves promotion sees it as his biggest achievement in a short successful management career but also a fairly illustrious playing career too. Russ Penn made over 280 appearances as a player in the football league and almost the same again as a non league player and 8 England C caps and now has over 130 games a gaffer under his belt too so he's seen a fair bit of football in his time but this weekend is a big one in the National North play-off. A trip to Brackley and some 90 minutes plus add-ons, and perhaps extra time and penalties stand between them and a place back in the top tier of non league football. Rounding up the week's news this time around it's Jon Couch from the Non League Paper. Plenty on the National League play-offs, how we got here and what lies ahead this weekend, plus a managerial merry-go-round that seems impossible to keep up with and some club administration news good and bad this week and the big stories of this weekend's Non League paper.
Luke is joined by Rob Worrall and Christian James to look back at Late Late winners for Chesterfield and Notts County. They hear from Chesterfield goalkeeper Ross Fitzsimons and defeated Bromley manager Andy Woodman. It was joy for Kidderminster and Brackley and we hear from goalscorer George Carline and interming manager Gaz Dean Subscribe via all good podcasting platforms Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit podcastchoices.com/adchoices
This is Garrison Hardie with your CrossPolitic Daily Newsbrief for Wednesday, February 15th, 2023. Fight Laugh Feast Conference - Ark Encounter This year, our Fight Laugh Feast Conference is at the Ark Encounter in Kentucky on The Politics of Six Day Creation. The politics of six day creation is the difference between a fixed standard of justice and a careening standard of justice, the difference between the corrosive relativism that creates mobs and anarchy and the freedom of objectivity, truth, and due process. The politics of six day creation establishes the authority and sufficiency of God’s Word for all of life: from what is a man or a woman, when does human life begin, and how is human society best organized? Come hear Ken Ham, Pastor Doug Wilson, Dr. Ben Merkle, Dr. Gordon Wilson, me and more, and of course a live CrossPolitic show! Mark your calendars for October 11th-14th, as we fight, laugh, and feast, with beer & psalms, our amazing lineup of speakers, our Rowdy Christian Merch, and a Sabbath Feast to wrap up the occasion. Maybe an infant baptism while we’re at it? https://www.zerohedge.com/political/ohios-apocalyptic-chemical-disaster-rages "Get The Hell Out Of There" - Ohio's Chemical Disaster Rages On While the US government is dispensing millions of dollars in resources to treat balloons as an existential crisis, a small town in Ohio finds itself engulfed in what actually looks like the apocalypse. Perhaps by design, all of the drama surrounding violations of US airspace by Chinese spy initiatives has done well to keep what is becoming one of the worst environmental disasters in recent memory from getting any headlines. The chaos began early last week when a train of more than 100 cars derailed in East Palestine, Ohio near the state’s border with Pennsylvania with roughly 5,000 residents. The accident launched fifty of those hundred freight cars from the tracks. Twenty of the freight cars on the train were carrying hazardous materials, ten of which were derailed. While the accident had no fatalities, of those ten cars, five contained pressurized vinyl chloride, a highly flammable carcinogenic gas. https://youtu.be/DHiXZUgQEwc - Play Video In order to address the volatile scenario around the crash site, the Ohio Emergency Management Agency executed its plan of venting the toxic gas with a controlled burn in order to evade an uncontrolled explosion which presented the risk of catastrophic damage. “Within the last two hours, a drastic temperature change has taken place in a rail car, and there is now the potential of a catastrophic tanker failure which could cause an explosion with the potential of deadly shrapnel traveling up to a mile,” Gov. Mike DeWine warned in statement explaining the decision to take action to avert widespread devastation. However, that operation sent large plumes of smoke containing vinyl chloride, phosgene, hydrogen chloride, and other gases into the air as the flames from the controlled burn raged on for days. Phosgene in particular is a highly toxic gas that can cause vomiting and respiratory trouble. The toxicity of phosgene gas is so potent that it was previously used as a chemical weapon during the First World War. https://twitter.com/i/status/1625155991724605440 - Play Video The hazardous airborne chemicals prompted officials to issue mandatory evacuation and shelter-in-place orders within a one-mile radius of where the train derailed. Those orders forced nearly 2,000 residents of East Palestine out of their homes. Despite the public safety risk in proximity to the crash site, over 500 people within the parameters of the evacuation order refused to leave their homes. However, those orders were lifted on February 8th, allowing residents to return to the area adjacent to the disaster. Dead fish are being pulled from rivers outside East Palestine, Ohio. The trucks doing the work are labeled EnviroScience, an Ohio-based company that provides "time-sensitive solutions to environmental challenges." https://twitter.com/i/status/1625214717945057282 - Play Video Amanda Breshears found her chickens dead ten miles from East Palestine. https://twitter.com/i/status/1625214716443504641 - Play Video Holzer’s concerns were echoed by reports from other residents who described similar conditions near their own properties. One of those residents was Katlyn Schwarzwaelder, the operator of a local dog kennel in nearby Darlington, Pennsylvania. The catastrophe caused her to leave her home despite the fact that it lies more than 10 miles away from the site of the controlled burn. After fleeing to Boardman, Ohio, 15 miles away from the derailment, Schwarzwaelder stated she received multiple reports of dead chickens, fish, and other animals from friends and acquaintances. One affected resident told Schwarzwaelder that they let their 2-year old dog out to use the bathroom only for it never to return. When they embarked upon a search for their missing pet, they found it dead in their yard. Testimony from Holzer, Schwarzwaelder, and others paints a drastically different picture than the official narrative tailored by officials who assured residents that the situation was under control. The poor air quality presents short and long term health risks to the public considering the carcinogenic effects of the chemicals. Carcinogens like vinyl chloride can cause cancer in organs including the liver, according to Kevin Crist, a professor of chemical and biomolecular engineering who also serves as the Director of Ohio University’s Air Quality Center. The magnitude of this story has been seemingly scrubbed from the public view as national media outlets continue to run sensationalist headlines about issues that look innocuous in comparison. It is an instance of history being rewritten in real time, setting a precedent that would allow victims of other widespread devastation to be swept under the rug. However, the scenes of the horror engulfing this small town in America’s heartland may prove to make this disaster impossible to ignore, rightfully putting the spotlight on the shortcomings of state and federal agencies tasked with emergency response management whose continued lack of accountability enables them to fail the American public time and time again. Before I move on, I want to remind everyone, that the federal government isn’t who we should be relying on. All their authority was granted by our creator. It’s our Lord and savior Jesus Christ who our faith must lie upon. So we take our prayer requests about Ohio to our Lord. CrossPolitic Email List: Are you subscribed to our CrossPolitic email list? If you’re not you really should be. Being subscribed to our email list means you won’t miss any updates about CrossPolitic or the Fight Laugh Feast Network! You’ll hear about what’s on the schedule for the week, live events, conference updates, Rowdy Christian Merch, updates from other shows within the Fight Laugh Feast Network, and you’ll hear from sponsors on the show, as they seek to take dominion for God’s Kingdom in the business world. To subscribe, simply enter your email address at the bottom of the page at fightlaughfeast.com. Again, that’s fightlaughfeast.com. https://www.yahoo.com/now/us-sell-26-million-more-200426064.html?guccounter=1&guce_referrer=aHR0cHM6Ly9ib25naW5vcmVwb3J0LmNvbS8&guce_referrer_sig=AQAAAIRfGaa1QNkAfNxqnKns3HFDpurTPZEMAJQbZHkm9Kd8dvCnqjRS3cHiKD959zLzu9NcskeVkzAiZKU6-n5SA1uQw2mlegpwCbky6OuwDVOwvPMNPu1RNebs3YtTmaKn3QVrOwnVrhWKovrJhtBzNcYaY6q1wDmiRxlbXfOk4Udi US to Sell 26 Million More Barrels From Strategic Oil Reserve The Biden administration plans to sell more crude oil from the Strategic Petroleum Reserve, fulfilling budget directives mandated years ago that it had sought to stop as oil prices have stabilized. The congressionally mandated sale will amount to 26 million barrels of crude, according to people familiar with the matter. The sale is in accordance with a budget mandate enacted in 2015 for the current fiscal year, said a spokesperson for the Department of Energy. The Energy Department has sought to stop some of the sales required by 2015 legislation so that it can refill the emergency reserve, which currently has about 371 million barrels. After this latest release, the reserve will dip to about 345 million. Biden officials decided last year to tap 180 million barrels from the strategic reserve in an effort to ease supply issues after Russia invaded Ukraine, upending global oil flows and sending crude above $100 a barrel. Some Republicans have criticized the Biden administration for that drawdown, which was the biggest release ever and helped drain the SPR to its lowest level since 1983. Critics admonished the move as a political stunt intended to combat rising gasoline prices ahead of midterm elections. Biden officials have since spoken with energy companies about purchasing oil to refill the SPR when prices approach $70 a barrel. The latest release comes after Russia unveiled plans to curtail production by half-a-million barrels a day next month to retaliate against sanctions. Russia’s move, which was downplayed by the European Union, follows China’s rapid economic reopening with the scrapping of Covid-19 restrictions. The SPR release may give pause to the OPEC+ alliance, which earlier said that global oil markets remain balanced. So how did the market react? The US House last month passed legislation meant to curb the Energy secretary’s ability to use the reserve unless the government increases the amount of federal lands available for gas and oil drilling. Other congressionally required releases — about 140 million barrels slated for fiscal years 2024 through 2027 — were canceled at the Energy Department’s behest after lawmakers in December approved a provision in a giant spending bill. West Texas Intermediate, the US benchmark for crude, fell 1% to trade near $79 a barrel after the announcement of more barrels. https://thepostmillennial.com/breaking-suspect-in-michigan-state-university-shooting-found-dead-from-self-inflicted-gunshot-at-least-3-people-killed?utm_campaign=64487 Suspect in Michigan State University shooting found dead from self-inflicted gunshot, at least 3 people killed The suspect in the Michigan State University shooting was found dead off campus late Monday night from an apparent self-inflicted gunshot wound. MSU Police Interim Deputy Chief Chris Rozman said, “There is no longer a threat on campus and the shelter-in-place has been lifted.” Police had earlier described the suspect as a "black male, shorter in stature, red shoes, jean jacket, wearing a baseball cap that is navy with a lighter brim." Rozman said the deceased individual matched the description of the suspect but did not reveal the suspect's identity. During a press conference late Monday night, Rozman said 3 people had been killed and 5 have been hospitalized. The victims, some in critical condition, were transported to Sparrow Hospital. Police responded to reports of an active shooting at Michigan State University in East Lansing Monday night and students were ordered to shelter in place. The incident took place at 8:18 pm inside Berkey Hall the location of MSU's Department of Sociology on the northern boundary of the campus. The shelter-in-place order went out at 8:31 pm telling students to stay inside and barricade themselves. "Run, Hide, Fight. Run means evacuate away from danger if you can do so safely, Hide means to secure-in-place, and Fight means protect yourself if no other option," MSU said in the alert. According to authorities, the suspect walked to the MSU Union, approximately 19 minutes away from the initial shooting site and opened fire. Hundreds of officers from the FBI, ATF, Michigan State Police, and other agencies are still assisting on campus. All campus activities have been canceled for 48 hours and authorities have asked people not to come to the campus on Tuesday. Now that was some heavy subject matter, so let’s go ahead and end with this… this is the fight laugh feast network afterall! https://www.theguardian.com/uk-news/2023/feb/14/man-facing-jail-over-theft-of-almost-200000-cadbury-creme-eggs Man facing jail over theft of almost 200,000 Cadbury Creme Eggs A chocolate thief is facing jail after admitting he stole almost 200,000 Cadbury Creme Eggs in a heist worth more than £31,000. Joby Pool, 32, dubbed “the Easter bunny” by police, used a stolen lorry cab to make off with chocolate after breaking into a Telford industrial unit with a metal grinder on Saturday. He is expected to be jailed for about two years next month, after pleading guilty to theft and criminal damage. Opening the facts of the case on Tuesday, prosecutor Owen Beale told Kidderminster magistrates court: “I don’t know if you have seen the news recently – there was a load that was stolen and on the trailer was Cadbury’s products, a large number of Creme Eggs.” He said Pool, a self-employed ground worker, used a tractor unit that had been stolen in the Yorkshire area in October to tow away the trailer full of chocolate, which was then driven away, eventually reaching the northbound M42. Pool was spotted by police and “gave up at junction 11 and walked towards the police with his hands up. He was arrested and the load was recovered”. “This clearly wasn’t spur-of-the-moment offending, if I can put it like that, because he had taken with him a tractor unit and he had to know that the load was there in the first place,” said Beale. Magistrates were told Pool, from West Yorkshire, was previously convicted of theft, handling stolen goods and driving while disqualified in 2019. Beale said: “This is clearly an organised criminal matter. You don’t just happen to learn about a trailer with that kind of value being available.” Defence solicitor John McMillan, told the court that Pool understood a substantial sentence was likely. In a series of tweets on Monday, West Mercia police described the incident as an “eggs-travagent theft” of a “chocolate collection box”. “Shortly after the theft a vehicle, presumably purporting to be the Easter bunny, was stopped northbound on the M42 and a man was arrested on suspicion of theft,” they said. Pool will be sentenced at Shrewsbury crown court on 14 March.
This is Garrison Hardie with your CrossPolitic Daily Newsbrief for Wednesday, February 15th, 2023. Fight Laugh Feast Conference - Ark Encounter This year, our Fight Laugh Feast Conference is at the Ark Encounter in Kentucky on The Politics of Six Day Creation. The politics of six day creation is the difference between a fixed standard of justice and a careening standard of justice, the difference between the corrosive relativism that creates mobs and anarchy and the freedom of objectivity, truth, and due process. The politics of six day creation establishes the authority and sufficiency of God’s Word for all of life: from what is a man or a woman, when does human life begin, and how is human society best organized? Come hear Ken Ham, Pastor Doug Wilson, Dr. Ben Merkle, Dr. Gordon Wilson, me and more, and of course a live CrossPolitic show! Mark your calendars for October 11th-14th, as we fight, laugh, and feast, with beer & psalms, our amazing lineup of speakers, our Rowdy Christian Merch, and a Sabbath Feast to wrap up the occasion. Maybe an infant baptism while we’re at it? https://www.zerohedge.com/political/ohios-apocalyptic-chemical-disaster-rages "Get The Hell Out Of There" - Ohio's Chemical Disaster Rages On While the US government is dispensing millions of dollars in resources to treat balloons as an existential crisis, a small town in Ohio finds itself engulfed in what actually looks like the apocalypse. Perhaps by design, all of the drama surrounding violations of US airspace by Chinese spy initiatives has done well to keep what is becoming one of the worst environmental disasters in recent memory from getting any headlines. The chaos began early last week when a train of more than 100 cars derailed in East Palestine, Ohio near the state’s border with Pennsylvania with roughly 5,000 residents. The accident launched fifty of those hundred freight cars from the tracks. Twenty of the freight cars on the train were carrying hazardous materials, ten of which were derailed. While the accident had no fatalities, of those ten cars, five contained pressurized vinyl chloride, a highly flammable carcinogenic gas. https://youtu.be/DHiXZUgQEwc - Play Video In order to address the volatile scenario around the crash site, the Ohio Emergency Management Agency executed its plan of venting the toxic gas with a controlled burn in order to evade an uncontrolled explosion which presented the risk of catastrophic damage. “Within the last two hours, a drastic temperature change has taken place in a rail car, and there is now the potential of a catastrophic tanker failure which could cause an explosion with the potential of deadly shrapnel traveling up to a mile,” Gov. Mike DeWine warned in statement explaining the decision to take action to avert widespread devastation. However, that operation sent large plumes of smoke containing vinyl chloride, phosgene, hydrogen chloride, and other gases into the air as the flames from the controlled burn raged on for days. Phosgene in particular is a highly toxic gas that can cause vomiting and respiratory trouble. The toxicity of phosgene gas is so potent that it was previously used as a chemical weapon during the First World War. https://twitter.com/i/status/1625155991724605440 - Play Video The hazardous airborne chemicals prompted officials to issue mandatory evacuation and shelter-in-place orders within a one-mile radius of where the train derailed. Those orders forced nearly 2,000 residents of East Palestine out of their homes. Despite the public safety risk in proximity to the crash site, over 500 people within the parameters of the evacuation order refused to leave their homes. However, those orders were lifted on February 8th, allowing residents to return to the area adjacent to the disaster. Dead fish are being pulled from rivers outside East Palestine, Ohio. The trucks doing the work are labeled EnviroScience, an Ohio-based company that provides "time-sensitive solutions to environmental challenges." https://twitter.com/i/status/1625214717945057282 - Play Video Amanda Breshears found her chickens dead ten miles from East Palestine. https://twitter.com/i/status/1625214716443504641 - Play Video Holzer’s concerns were echoed by reports from other residents who described similar conditions near their own properties. One of those residents was Katlyn Schwarzwaelder, the operator of a local dog kennel in nearby Darlington, Pennsylvania. The catastrophe caused her to leave her home despite the fact that it lies more than 10 miles away from the site of the controlled burn. After fleeing to Boardman, Ohio, 15 miles away from the derailment, Schwarzwaelder stated she received multiple reports of dead chickens, fish, and other animals from friends and acquaintances. One affected resident told Schwarzwaelder that they let their 2-year old dog out to use the bathroom only for it never to return. When they embarked upon a search for their missing pet, they found it dead in their yard. Testimony from Holzer, Schwarzwaelder, and others paints a drastically different picture than the official narrative tailored by officials who assured residents that the situation was under control. The poor air quality presents short and long term health risks to the public considering the carcinogenic effects of the chemicals. Carcinogens like vinyl chloride can cause cancer in organs including the liver, according to Kevin Crist, a professor of chemical and biomolecular engineering who also serves as the Director of Ohio University’s Air Quality Center. The magnitude of this story has been seemingly scrubbed from the public view as national media outlets continue to run sensationalist headlines about issues that look innocuous in comparison. It is an instance of history being rewritten in real time, setting a precedent that would allow victims of other widespread devastation to be swept under the rug. However, the scenes of the horror engulfing this small town in America’s heartland may prove to make this disaster impossible to ignore, rightfully putting the spotlight on the shortcomings of state and federal agencies tasked with emergency response management whose continued lack of accountability enables them to fail the American public time and time again. Before I move on, I want to remind everyone, that the federal government isn’t who we should be relying on. All their authority was granted by our creator. It’s our Lord and savior Jesus Christ who our faith must lie upon. So we take our prayer requests about Ohio to our Lord. CrossPolitic Email List: Are you subscribed to our CrossPolitic email list? If you’re not you really should be. Being subscribed to our email list means you won’t miss any updates about CrossPolitic or the Fight Laugh Feast Network! You’ll hear about what’s on the schedule for the week, live events, conference updates, Rowdy Christian Merch, updates from other shows within the Fight Laugh Feast Network, and you’ll hear from sponsors on the show, as they seek to take dominion for God’s Kingdom in the business world. To subscribe, simply enter your email address at the bottom of the page at fightlaughfeast.com. Again, that’s fightlaughfeast.com. https://www.yahoo.com/now/us-sell-26-million-more-200426064.html?guccounter=1&guce_referrer=aHR0cHM6Ly9ib25naW5vcmVwb3J0LmNvbS8&guce_referrer_sig=AQAAAIRfGaa1QNkAfNxqnKns3HFDpurTPZEMAJQbZHkm9Kd8dvCnqjRS3cHiKD959zLzu9NcskeVkzAiZKU6-n5SA1uQw2mlegpwCbky6OuwDVOwvPMNPu1RNebs3YtTmaKn3QVrOwnVrhWKovrJhtBzNcYaY6q1wDmiRxlbXfOk4Udi US to Sell 26 Million More Barrels From Strategic Oil Reserve The Biden administration plans to sell more crude oil from the Strategic Petroleum Reserve, fulfilling budget directives mandated years ago that it had sought to stop as oil prices have stabilized. The congressionally mandated sale will amount to 26 million barrels of crude, according to people familiar with the matter. The sale is in accordance with a budget mandate enacted in 2015 for the current fiscal year, said a spokesperson for the Department of Energy. The Energy Department has sought to stop some of the sales required by 2015 legislation so that it can refill the emergency reserve, which currently has about 371 million barrels. After this latest release, the reserve will dip to about 345 million. Biden officials decided last year to tap 180 million barrels from the strategic reserve in an effort to ease supply issues after Russia invaded Ukraine, upending global oil flows and sending crude above $100 a barrel. Some Republicans have criticized the Biden administration for that drawdown, which was the biggest release ever and helped drain the SPR to its lowest level since 1983. Critics admonished the move as a political stunt intended to combat rising gasoline prices ahead of midterm elections. Biden officials have since spoken with energy companies about purchasing oil to refill the SPR when prices approach $70 a barrel. The latest release comes after Russia unveiled plans to curtail production by half-a-million barrels a day next month to retaliate against sanctions. Russia’s move, which was downplayed by the European Union, follows China’s rapid economic reopening with the scrapping of Covid-19 restrictions. The SPR release may give pause to the OPEC+ alliance, which earlier said that global oil markets remain balanced. So how did the market react? The US House last month passed legislation meant to curb the Energy secretary’s ability to use the reserve unless the government increases the amount of federal lands available for gas and oil drilling. Other congressionally required releases — about 140 million barrels slated for fiscal years 2024 through 2027 — were canceled at the Energy Department’s behest after lawmakers in December approved a provision in a giant spending bill. West Texas Intermediate, the US benchmark for crude, fell 1% to trade near $79 a barrel after the announcement of more barrels. https://thepostmillennial.com/breaking-suspect-in-michigan-state-university-shooting-found-dead-from-self-inflicted-gunshot-at-least-3-people-killed?utm_campaign=64487 Suspect in Michigan State University shooting found dead from self-inflicted gunshot, at least 3 people killed The suspect in the Michigan State University shooting was found dead off campus late Monday night from an apparent self-inflicted gunshot wound. MSU Police Interim Deputy Chief Chris Rozman said, “There is no longer a threat on campus and the shelter-in-place has been lifted.” Police had earlier described the suspect as a "black male, shorter in stature, red shoes, jean jacket, wearing a baseball cap that is navy with a lighter brim." Rozman said the deceased individual matched the description of the suspect but did not reveal the suspect's identity. During a press conference late Monday night, Rozman said 3 people had been killed and 5 have been hospitalized. The victims, some in critical condition, were transported to Sparrow Hospital. Police responded to reports of an active shooting at Michigan State University in East Lansing Monday night and students were ordered to shelter in place. The incident took place at 8:18 pm inside Berkey Hall the location of MSU's Department of Sociology on the northern boundary of the campus. The shelter-in-place order went out at 8:31 pm telling students to stay inside and barricade themselves. "Run, Hide, Fight. Run means evacuate away from danger if you can do so safely, Hide means to secure-in-place, and Fight means protect yourself if no other option," MSU said in the alert. According to authorities, the suspect walked to the MSU Union, approximately 19 minutes away from the initial shooting site and opened fire. Hundreds of officers from the FBI, ATF, Michigan State Police, and other agencies are still assisting on campus. All campus activities have been canceled for 48 hours and authorities have asked people not to come to the campus on Tuesday. Now that was some heavy subject matter, so let’s go ahead and end with this… this is the fight laugh feast network afterall! https://www.theguardian.com/uk-news/2023/feb/14/man-facing-jail-over-theft-of-almost-200000-cadbury-creme-eggs Man facing jail over theft of almost 200,000 Cadbury Creme Eggs A chocolate thief is facing jail after admitting he stole almost 200,000 Cadbury Creme Eggs in a heist worth more than £31,000. Joby Pool, 32, dubbed “the Easter bunny” by police, used a stolen lorry cab to make off with chocolate after breaking into a Telford industrial unit with a metal grinder on Saturday. He is expected to be jailed for about two years next month, after pleading guilty to theft and criminal damage. Opening the facts of the case on Tuesday, prosecutor Owen Beale told Kidderminster magistrates court: “I don’t know if you have seen the news recently – there was a load that was stolen and on the trailer was Cadbury’s products, a large number of Creme Eggs.” He said Pool, a self-employed ground worker, used a tractor unit that had been stolen in the Yorkshire area in October to tow away the trailer full of chocolate, which was then driven away, eventually reaching the northbound M42. Pool was spotted by police and “gave up at junction 11 and walked towards the police with his hands up. He was arrested and the load was recovered”. “This clearly wasn’t spur-of-the-moment offending, if I can put it like that, because he had taken with him a tractor unit and he had to know that the load was there in the first place,” said Beale. Magistrates were told Pool, from West Yorkshire, was previously convicted of theft, handling stolen goods and driving while disqualified in 2019. Beale said: “This is clearly an organised criminal matter. You don’t just happen to learn about a trailer with that kind of value being available.” Defence solicitor John McMillan, told the court that Pool understood a substantial sentence was likely. In a series of tweets on Monday, West Mercia police described the incident as an “eggs-travagent theft” of a “chocolate collection box”. “Shortly after the theft a vehicle, presumably purporting to be the Easter bunny, was stopped northbound on the M42 and a man was arrested on suspicion of theft,” they said. Pool will be sentenced at Shrewsbury crown court on 14 March.
In our now annual tradition, we assembled to tackle the most bizarre football quiz questions imaginable!
He's here, he's there; Dr. Hillman brings drug safety everywhere! So given the rules and regulations he needs to follow, the title “vigilante” could be nothing but ironic.We chart David's progress through choosing pharmacology as a subject to study, and settling on pharmacovigilance as a career to pursue. Listen: The Bollywood beats come courtesy of Cambridge-based artist Anish Kumar whose music you can also find on Bandcamp: anishkumarmusic.bandcamp.com, YouTube, Instagram and Twitter.Watch:Subscribe to our YouTube channel now for all future recordings. Episode transcript[Background intro music playing is "Nazia" by Anish Kumar]Parmvir: Hello everyone. And welcome to another episode of the 2Scientists podcast, where inspiring scientists share their work with you, wherever you like to listen. Today we come to you from a rather unique spot, rather than a cafe or bar we are camped out in Kensington Gardens in London, because it's a glorious day and our podcasting equipment allows us to do that. But enough about me and us, we are here today, of course I am your host Parmvir Bahia here and we're here with David Basanta, but we also have with us another David who is very special to me, he is an old friend of mine from my PhD program, and we shared much time and much swearing over experiments together at University college London. How are you David Hillman? David: I'm doing well. Thank you. It's, as you say, it's a, it's a lovely day and, it's nice to be back with old friends. Parmvir: Yes, yes. Of course everything rotates background to COVID and whereas we would normally see each other once a year. It's been three, four, possibly? David: Three, I think that's yeah.Parmvir: Miserable. David: Yeah. Sad times we shall have to make up for it. Parmvir: We will, we will. There's a bottle of Cava with our name on it. Once we've done with this. David: And onion rings. Parmvir: And onion rings. Yes. Fancy Marks and Spencer's one's though. So let's start at the beginning. I'm not talking about like, where were you born kind of thing. Although you can mention Kidderminster if you'd like. So as I understand it, we had a relatively similar track as undergraduates. So you did a bachelor's in pharmacology, correct? David: Yeah, that's right. Parmvir: So tell us why, why pharmacology? David: So this is gonna age me, age us.So I, for my A levels, so for my senior school exams, I, studied chemistry, biology, and maths, and I wanted to study something at university that combined chemistry and biology. And so this is the bit that will age us. So back in the day, if you remember, you would go to the, career advice department who were trying to help people to steer people towards what options they might want to pick at university.And they had this huge telephone directory effectively, which, mapped together people's different, combinations of A level courses and then gave you a list of options that you could, study at university. So I was sat in this little tiny room with this career advisor person, and they were basically running through this list of different courses.And when they came to pharmacology, they'd already mentioned pharmacy, which, you know, most people know what it is, but then they said pharmacology and I stopped them and said, well, what's, what's the difference? And they actually gave a pretty good summary. They said, it's more the biology of medicine. It's more the, the research and development of new medicines. They said it's potentially a controversial topic because it's the pharmaceutical industry is itself sometimes controversial and there's other aspects to the industry, which are, challenging sometimes. But yeah, that's how it started. So I picked a few different pharmacology courses, one of which was King's College London. I was always very practical, so I liked the idea of doing a year in industry at some point. So I chose a sandwich course like you and yeah, so that took me to KCL all that time ago. Parmvir: Mm. So I didn't realize how similar our tracks had been, because I also did biology, chemistry and maths, and I wanted to do something with the chemistry and the biology.And I got put in that direction by David: did you pick it out of the phone book as well? Parmvir: I did. What was it called? There was a name for it. David: It was pretty like a UCAS publication. Parmvir: Yes. It was just, it was enormous. David: Yeah. Parmvir: But yeah, in any case, I also, I did a sandwich year and I got to go and hang out in Germany for a year, which was fun.But yeah. So obviously after that you came to do a PhD at UCL where we were, well, I was a year ahead of you, I think. David: Yeah. You were. Parmvir: Why? Why did you do a PhD? David: So well for the reasons that I guess a lot of people do them, which is that I wasn't sure what to do next [both laugh] and a PhD seemed like a good way to string it out for another few years before I figured that out.But the reason I landed on UCL was that when I did go and do my year in industry, which like you was for a large pharma company, I worked in a lab looking at some non-clinical safety models. And we were using electrophysiology techniques at the time that was sharp electrode electrophysiology.Parmvir: You're gonna have to explain what electrophysiology means. David: Oh, don't make me do that. It's been 20 years [Parmvir laughs]. Oh, it's basically where you take either isolated cells or tissues and you put tiny, tiny electrodes into them and measure the changing currents across cell membranes. And as you put different drugs on, you can look at different effects of those drugs how they affect the electrical signals that you can measure.And really it's ions moving back and forward across membranes by little things called ion channels. So yeah, so I'd done sharp electrode electrophysiology there. I went back to university to finish my last year, and then the question came up about what to pick for a PhD. And I thought, well, although I hadn't enjoyed electrophysiology, it's something that I had started to, I guess, gain an interest in. Plus I had some skills that in that area. So, yeah, so I found a course, rather a PhD studentship at UCL, which seemed to fit the bill. It was looking at using a slightly different electrophysiology technique, so patch, clamping in a different area, but I thought it was something that I could use what I'd learnt in my year in industry Parmvir: I gave you some of these questions beforehand. David: Yes, because I'm incapable of spontaneous reaction to questions [Parmvir laughs]. Parmvir: Actually, I loved it so much that I have to read out your description of what your memory is like. David: I was quite proud of that. I coined that yesterday. I used to think of my memory as a lobster pot. Parmvir: All right. So you said I've just come up with a good analogy for my recall memory. It's like a reference library. You have to put in a request and then go away for a bit. When you come back, I'll have retrieved something from the vaults. Hopefully. David: Yeah, exactly. Parmvir: But aside from that I wanted to say this might be something of a loaded question, but what did you think of your PhD experience?David: You know, I really, I look back on those years with fond memory. Now it's partly because looking back, you edit out all of the stress and anxiety associated with doing a research project like that. I remember at the time when I first started UCL ran some induction courses where they pulled together PhD students and other postgraduate students from all sorts of backgrounds and John Foreman who you'll remember who was the Dean of students at the time, he gave a little introduction to UCL, but also gave some interesting advice let's say and pointers.And one of the things he pointed out in that session was the high degree of mental illness that is encountered by students in general taking these types of courses because they are stressful. And you often feel like you are kind of on your own. Driving your own research project forward. Sometimes through difficult times. So I do remember that in particular, but you know, what I remember mostly is just how impressed I was with all of the people that surrounded me because our department was not particularly flashy in its kind of presentation, but there were some seriously impressive people there.So I always like to think of our lab in the sense of, you know, it was run by effectively by Dennis and, and Guy when we got there. But before then it had been run by Don and before then it had been run by Bernard Katz who was a Nobel laureate. So it felt like we were the either grandchildren or great grandchildren of a Nobel Laureate and the whole department was a bit like that. It had a lot of very understated people who were world experts in their, in their field. And I always felt like the dumbest person in the department. But that didn't bother me too much because you know, being surrounded by all this greatness and even just, you know, the little glimpses of things you would see at the kind of coffee breaks and in the corridors, some of those memories still live with me, you know. Bearing in mind, this was back in what, between 2001 and 2005.So very, very early days of smartphones, things like trios and things like that, which seem antiquated now. But I remember coming across two old professors, so probably in their seventies or eighties comparing their smartphones and that like little microcosm, are the things that I loved about the department.Parmvir: Actually, I mean, I think you're, you're definitely selling yourself short. Like nobody would say that you weren't smart enough to be there. And I think one of the things that kind of ties into the, the mental health aspect is that we all felt that way. David: Yeah. Parmvir: Except we didn't express it to anyone else. It's, it's utterly ridiculous. How can we all be the least smart person in the room that's just not possible. David: Yeah. Parmvir: And after that, we all got our PhDs anyway, so, you know yeah. David: I certainly have no regrets about it. And I look back on those times with, with very fond memories, for sure. Parmvir: Yeah. Just talk briefly about what you did for your project and what the difficulties were.David: So the lab that I joined, so which, which you were a part of as well, their specialty was calcium activated potassium channels. And over time, the lab had looked at these ion channels in various different settings. The project that I was given was looking at these channels in vascular endothelial cells, which was a cell type that no one in the lab had ever studied before.Parmvir: Mm. David: So one of the biggest challenges that we were hit with straight away was that no one in the lab could really help that much with firsthand experience of how to obtain these cells, how to isolate them, how to culture them, how to grow them and really how to manage those cell types. So you might well remember that, the first, probably nine months of my PhD was just spent trying to culture these cells. Parmvir: Mm-hmm David: and it started with you know, available tissue from rats and other small mammals.But then eventually we were not having success with culturing cells from those models. So I switched onto pigs and, you know, I'd done a bit of reading that, you know, these vessels, because they were much larger the blood vessels, it was easier effectively to culture cells from, so I looked in the phone book and I found the address of an abattoir out in the middle of Essex.And there began my weekly trip for getting on for two and a half years to the deepest, darkest corners of Essex to go and retrieve pig, coronary artery cells once a week. Parmvir: Yeah. And essentially you suffered because these things were so flat. [David laughs] And when you're trying to, so you, for anyone who's listening, you have to picture trying to get a very, very fine tube onto something that is incredibly flat, and essentially you need this thing to form a vacuum seal and that just wasn't gonna happen. David: No, so, you know, vascular endothelial cells, they're the cells that line blood vessels, which is why they're, they're very flat. They're like tiles almost on the inside of veins and arteries.And you know, with other cells in the lab that were being looked at like the ones that you were looking at, like DRGs and like neurons and things like that, you know, you were basically putting the, the electrode down onto like a ball. Parmvir: Yeah. David: So the gap between the bottom of the dish and the top of the cell was who knows, 10, 20 microns, something like that. The cells that we were looking at, they flattened themselves out so much, they were about one micron, I think we estimated and therefore the tiniest vibration in the room would destroy the cell. And yeah, so the first stage was trying to culture, the damn things, and that was extremely challenging. It took a long time, but nine months of the way through managed it, and then began the whole pain of trying to get electrical recordings from them, which turned out to be as difficult. Parmvir: Yeah. So one of the things, I don't know if we ever talked about this, but what did you aspire to do after you'd done your PhD originally?Like, did you have any kind of idea? David: I mean, I think I was always headed into the pharmaceutical industry, which is where I landed up. In my undergrad degree in, I think my either first or second year, I did a very nice course, which was a kind of practical introduction to the pharmaceutical industry and from very top level, how drugs are developed and how pharma companies are organized internally and how the research progresses. And that, I'd always found that interesting. I mean, I find the entire pharmaceutical industry absolutely fascinating. And still do to this day. It's such an amazingly complex industry. And so, yeah, so I think I'd always been heading in that direction. Sure enough, the PhD certainly made me decide I was done with bench science [Parmvir laughs]. So, you know, by the time you've spent three plus years plodding along with these experiments that have a success rate of one in 50 sometimes. Parmvir: Yeah. David: You know, days and weeks without getting any data, and towards the end, still being in the lab at three o'clock in the morning, trying to get something to work and breaking more and more glassware as time goes on [Parmvir laughs]Yeah, I decided I was done with bench science, although I loved being in the labs, I loved playing in the labs. But I was never that into the kind of reading of the scientific papers and that sort of thing. Once it came down to maths and things like that, I wasn't so engaged. I needed to see practical things. Parmvir: Yeah. I feel like at some point we realized we were both some kind of engineer at heart rather than David: Yeah. Maybe Parmvir: scientist, David: maybe. Parmvir: It's more like, how does this work rather than trying to answer a bigger scientific question. David: Yeah. Parmvir: But obviously you were, you were a little bit scarred by your experience there, and you ended up going off in, I guess, a very different track from what the standard academic education leads you towards. So I think at this point this might be a good place to put your disclaimer in. David: Yes. So I work in the pharmaceutical industry and over time I've worked for, and with a variety of different companies.Any of the content that I describe today are my opinions and my opinions alone, and often they're really based off things which are in the public domain. In fact it's all based off things that were in the public domain and also some of the education that I've received, because actually, even after I finished my PhD, I then years later went on to study a, another academic course specifically in pharmacovigilance and pharmacoepidemiology.Parmvir: Oh, where did you do that? David: London school of Hygiene and Tropical Medicine. Parmvir: Oh. David: And it's interesting because it's a short course and I felt was a very valuable course. It's a course where regulatory authorities also send their people to learn too. Parmvir: So there's a lot of questions I can ask next.But one of the things that your job description throws up is this word "pharmacovigilance". What does that mean? David: Okay. So somewhere because I'm not gonna do it justice from memory, I'm going to read out the WHO definition of pharmacovigilance. It doesn't roll off the tongue, unfortunately, which is why it's never quite there in my head.So per the WHO: pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other medicine, or vaccine-related problem. So essentially it is the process and the science relating to drug side effects. Now as you'll remember from pharmacology days, very early on, you're taught that all pharmacologically active substances, if it applies to the human body have side effects. The same side effects are not encountered by every person.And you know, some of the side effects might have obvious clinical manifestations. Some might not, you might get side effects, never know you've had them. And of course they vary massively in severity. So when you are looking at a medicine, particularly one that you're introducing to kind of general use in humans, you have a trade-off to make because you have an expected therapeutic benefit, but you also have to be mindful of potential side effects, particularly serious side effects and how much tolerance you have for those versus the good that the drug is supposed to do.And achieving that balance is one of the big challenges that's faced in drug development.Parmvir: So what you do really, it kind of comes at the end of the whole process of clinical trials and so on for given products, right? David: It actually starts right at the beginning of clinical development.So. Parmvir: Oh, hang on, I have to ask David's question: does that make you a Pharmacovigilante? David: [David and Parmvir laugh] I've often wondered the same thing myself. But yeah, so pharmacovigilance takes off really where toxicology leaves. So before you can put a drug into clinical development, by which I mean development in humans, drugs first have to go through preclinical development and that's where all the various toxicology studies are run.Parmvir: Can you quickly define toxicology for us? David: Sure. It is really focusing on the well, the potentially toxic side of medicines. So before you put a drug anywhere near a human, you want to be absolutely certain that it doesn't cause various catastrophic side effects in humans.So, for example, you need to be confident that it doesn't cause cancer. You need to be confident that it's not gonna cause a heart attack immediately, or cause a stroke immediately or things like that. So as per regulations in pretty much every country in the world, before you put a drug anywhere near a human in a clinical trial, it has to go through a standard set of tests.And there's various ways to achieve that. You know, sometimes those are tests using computer simulated models. Sometimes they are using individual cells or cultured cells or tissues. And sometimes as is well known in the industry they're using animal models and these are legally required tests.So every drug that goes through the process has to go through these. So that's done before it gets to clinical development. And then you start with phase one clinical trials which are studies on, usually on healthy volunteers and they're very small trials. They involve perhaps a few tens of patients. And the only purpose of those trials is to look at the safety and tolerability of the drug. So this is the first time you're putting the drug into humans. There is a bit of an exception to that. So although these are usually conducted on healthy volunteers, for some drugs, including, for example oncology drugs. Those drugs are usually along the more kind of toxic end of agents, so it's not ethical to put those into healthy volunteers. So sometimes those studies are conducted in a patient population. So once a drug moves into human studies into phase one, from that point, really for the rest of the lifetime of that drug as a human medicine pharmacovigilance is involved. So all the way through the phase one, two and three studies and then once the drug goes onto the market, pharmacovigilance continues.So the companies or the pharmaceutical or biotech companies that are developing these assets have a legal requirement to collect and analyze this data on an ongoing basis pretty much forever. Until that drug is eventually, perhaps if it's lucky enough to get to the market, until it's withdrawn from the market, perhaps many decades later.Parmvir: Very good. And I think that there are probably some very topical things that have come up recently as a result of COVID 19, which is important to consider when we're talking about these things, in that we are not just relying on these clinical trials that have gone out to ensure that these things are safe, but once they're out there that you have to continue to get feedback from people who are taking these to ensure that they continue to be safe in the long term, right?David: That's true. So, you know, ordinarily in clinical development, once you get through phase 1, 2, 3, and if you are lucky enough to have a drug, which is sufficiently efficacious, tolerable to go to market, then yes, you know, the drug's released to market and you continue to monitor for this stuff.Vaccines are in a particularly special category because they are drugs that are given to healthy people. Mm yes. And so therefore the benefit risk balance is more complicated in some ways, because , you know, it's, it's hard to consider the benefit to the individual of taking a product when they don't yet have that disease.So now there are other drugs that are in a similar category, other drugs that are given to healthy people. This is where I can ask you some questions. So what, what do you think those other drugs include? Parmvir: Oh, goodness. Um, I'm trying to think off the top of my head, what they might be. David: Yeah. It's very unfair. Parmvir: All I can think of at the moment are the other vaccines. David: Okay. So, Parmvir: but there are lots of prophylactic things. Yeah. Yeah. I can't think of anything David: Contraceptives. Parmvir: The obvious prophylactic. Yes. David: Drugs used for travel. So things like anti-malaria tablets. Parmvir: Oh yeah. David: Drugs used for things like smoking cessation Parmvir: mm-hmmDavid: stuff like that.So again, these are all drugs that are generally given to healthy people. So, you know, and this is where benefit risk balance comes into sharp focus, because if you have a drug that has been developed to treat a very hard to treat cancer, let's say, then when you consider benefit risk balance you know, if these patients are effectively going to die without a treatment, and this is the only treatment available, you might be able to accept that a drug has a one in a hundred chance of causing a fatal stroke. Particularly if that drug is given in hospital and these things can be, can be managed. If however, you are developing a cough medicine, then your tolerance for any type of dangerous side effects is basically zero, and of course, many drugs elsewhere on that scale. So yeah, benefit risk balance is a key part of what has to be looked at during drug development. And yeah, as we say, vaccines are particularly challenging. Often these days when a new drug is developed the clinical development and the studies don't stop necessarily when the drug is released for marketing. So, often as a condition of the marketing authorizations that are granted for these drugs, there have to be continuing studies to look at safety. These are called post-authorization safety studies. And so there's ongoing collection of data in a rigorous way to keep monitoring for various things. Either new things that we didn't know about the drug before, because of course when you're in clinical development, your number of patients is normally quite small Parmvir: mm-hmm David: so you're less likely to spot very rare side effects. You wouldn't usually detect a one in 50,000 probability side effect in a clinical trial cohort. Parmvir: Yeah. David: But sometimes these post authorization safety studies allow you to pick up more of that and enable you to characterize some of the side effects that you do know about more in detail.Parmvir: Yeah. So David B here asks essentially how long do these things go on after the drug's been on the market? For example, is there still pharmacovigilance for aspirin? David: Yes. Every single drug that has a marketing authorization out there it is the law in pretty much every country in the world that all safety data that becomes available to the marketing authorization holders, that's the company that owns the rights to the drug and effectively sells the drug, they're required by law to collect process, analyze and report this data. Now as drugs age, the natural reporting rate for some of these drugs drops so the probability of a physician or a pharmacist or a nurse, or even a patient reporting a side effect probably drops over time because theses are not new medicines anymore, but even so, any data that is collected has to go through that process, which is the pharmacovigilance that we were referring to earlier. In addition to that, all companies with marketing authorizations have to look at scientific and medical literature. It all has to be reviewed, so in European requirements, including the UK on a weekly basis, companies have to trawl some of the big literature databases, such as PubMed and M base, they have to trawl that information for any articles on their drugs. And any indication of side effects or other similar challenges. Parmvir: So how is this information collected and processed? Cause you've said obviously doctors, nurses, patients, they will all report certain things. Mm-hmm how do you kind of get them to a central place and cataloged and how do you decide what are actual side effects versus David: So if we think about the front end of the process, most pharma companies out there will have medical information help lines. So these are help lines that are set out there so that healthcare professionals. So that's the physicians, the, the pharmacists, the nurses and others but also consumers can contact the company for more information about the medicine and also potentially report adverse events, side effects. In parallel to that the same thing's going on with the regulators. So in the UK, for example, we have the yellow card scheme, which these days is a web portal system where anyone can go in and report side effects of medicines they're taking. In the us, you have the MedWatch scheme, which is very similar. Most companies around the world have similar things. Plus you've also got ongoing clinical trials, clinical studies, so data is coming in that way too. We've got data coming in from literature that I've mentioned. The regulators, when they receive stuff directly, they often pass that information over to the pharma company.So essentially all this information is coming towards the pharma company. It all gets directed to a pharmacovigilance department. And then we go through the process of processing that data. And so that data comes in from everywhere around the world where the drug is available for patients to take both in clinical trials and on the market.So the process basically consists of firstly translating the data, if it needs to be translated that gets captured into a safety database and there are various commercial safe databases out there. This is where companies collate all the information received on their drugs. And it goes through a process whereby data is kind of standardized it's put into standard terminology in a way that is compatible with the regulatory requirements. A narrative is constructed. So we write a story of what's happened to the patient from beginning to end. We look at various things like if the information is available to us, you know, what other medications were the patients taking? What's their medical history? What was the sequence of events? So what was the time to onset if possible, if we have that information between the patient taking the drug and them reporting the side effect, what the clinical course of the side effect was, so did the patient recover? Was any adjustment made to the the, the dosing or any treatments given? And so all that gets written up, we then decide what other information do we need to know?And then there's a feedback loop to go and ask the reporter if they'll provide additional information. Usually we ask for more information on more serious adverse events. We don't wanna overburden the reporters. Now reporters in clinical trials, so physicians involved in those, they're legally obliged to help with that process. Spontaneous reporters that we refer to, which is just where any healthcare professional or consumer contacts, the company, that's a voluntary reporting system, so we can ask them for additional information, they don't have to provide it, but we have to ask the questions anyway. So the information gets pulled together. It then goes, usually goes through a medical review, so we have kind of scientists pulling the data together. And then we have physicians reviewing the case, making sure it makes medical sense. And then depending on the seriousness of the case and other attributes, that case might have to be reported out to regulators worldwide.And a lot of the reports which are serious, have to be reported out within 15 days of what we call day zero, which is the first day anyone in the company became aware of the report. Parmvir: Mm-hmm. David: But to give you an idea, the large pharma companies are dealing with potentially tens of thousands of reports a week that are coming in on all of their products. So these are vast systems that are set up and they have to be set up to be able to meet all of the regulatory requirements in terms of timelines, for reporting. So the data's coming in, the expedited reports are going out in the format that the regulators require. We also have to pull together what we call aggregate reports. So these aggregated analyses of data over time for newer drugs, for example, those are submitted in Europe every six months. And then over time as the drug gets older, the gap between reports gets longer. And then also we're doing something, what we call signal section, which is where we are analyzing the data. And we're looking for trends in the data. Where we think we've got patterns we're starting to then look into researching those patterns a little bit more, you know, if we start to see, for example that I don't know that we are getting what appears to be a disproportionate number of nose bleeds, let's say, in a patient cohort, we would, you know, do background research on, well, you know, is there a plausible biological mechanism that we know about through the development of the drug? Was there stuff seen in the animal studies or even the human studies that might indicate that there's a, there's a root cause here.We'll look into confounding effects. Are all these patients on other drugs, which actually are likely causing that? And yeah, so kind of an appraisal is done: what's going on? Is it likely to be caused by something else? And if not, you know, we, keep on looking and those conversations then have to be shared with the regulatory authorities.And over time, what you'll see is the labeling of the product, the professional labeling which in Europe, including the UK, is the SMPC, the summary of product characteristics, which is a bit like the instruction manual for the product, which is available to healthcare professionals and the simplified version of that PIL those little leaflets you find inside of packs, those eventually get revised on an ongoing basis to accommodate the new knowledge that we are gaining on the side effect profile of the drug. So this is an ongoing process and it happens throughout the entire lifetime of the, of the drug. Parmvir: But yeah, so here's a subject that no one's talked about for a little while. COVID 19 David: mm-hmm Parmvir: [laughs] Obviously I know there's probably a collective groan from people listening right now, but it seems like a relevant subject, given the conversations around safety that people are having with regard to the vaccine. So do you know if there's been like a major uptick in these reports by individuals, of side effects from the vaccines, or do you take account of the fact that so many billions of people essentially at this point have received at least one shot of the vaccine versus how many reports you get coming in?David: Yeah. So this is one of the big challenges, and one of the things I should have said about drugs like vaccines is because they're given to such vast numbers of people, it becomes a particular challenge to differentiate between things which are being caused potentially by the vaccine and other things, which unfortunately are just bad luck of being a human being.And by that, I mean, so years ago when I was doing one of the academic courses we were being taught about the vast amounts of research that had to be done in terms of epidemiology before the HPV vaccines were released. So these vaccines were being released for use in teenage girls, and at the time it was felt that there was perhaps an insufficient understanding of the general health of that population, including things like what is the probability of a freak occurrence that a teenage girl is going to have a stroke or something like that? Things which we think of as of course, they're exceptionally rare, but they do happen.Parmvir: Mm-hmm David: and I'm talking about in untreated populations. Parmvir: Yep. David: But of course, you know, some of these patients are also on birth control and things like that, that also have other risk factors associated with them so my understanding is before the HPV vaccines were released, a huge amount of epidemiology research was done so that when the new vaccines were released, we knew that we would expect, and I'm just gonna make up a number here that, you know, one in 500,000 teenage girls would have, I don't know, some kind of fatal event which would just naturally occur, you know, even without them having the vaccine. And so that's similar for other vaccine rollouts as well. There has to be a good understanding of the background events of other things that, people will have happen to them, which have nothing to do with the medicine that you are giving.So, you know, that data is kept available and kept an eye on by the regulatory authorities and also the pharma companies. We don't have background rates for everything, so being prepared for what might come and then, you know, there perhaps isn't so much panic when the first case comes in of a patient that has one of these catastrophic events but if you start to see more than that, that's when you start to perhaps get more interested in: is this really being caused by the vaccine or the drug of interest. So, yeah, a lot of upfront work has to be done before you even put the drug out there. I mean, in terms of the COVID vaccines and the treatments, because of the high degree of public interest and scrutiny a lot of these drugs when they were first given and the vaccines were first given, so adverse events, side effects were tracked through post-authorization safety studies. So actually a lot of people, when they got their first doses, consented to have maybe a follow up call from an investigator who would ask them about various side effects that happened. So in addition to all of the natural spontaneous reporting that was coming in, there were very large cohorts of past study data coming in which is a robust way to look at these things. I know as well, there were legitimate questions about, you know, the COVID vaccines in particular were produced fairly quickly compared to the usual 10 to 15 years in development of, of a product. But you know, there are various reasons for this. So vaccines are perhaps one of the medicines where it's more possible to template out the product and therefore switch out components. But they still have a product which is similar to other products that have previously been used. But also, the COVID era in terms of vaccine development and treatment development was, in my opinion at least a completely unique event in terms of drug development so far. If you think of drug development as a kind of universe, or I'm gonna use some wonky analogies here, but let's say as galaxies, which have solar systems within them that have planets within them.So if you think of the galaxy of drug development you have all of these different stakeholders involved. You have the pharmaceutical companies and biotech companies and the service companies that support them, that's one area. You have the regulatory authorities but you have many other stakeholders.You have patients, of course they're the most important. For chronic diseases you might have patient advocacy groups. But also, you know, you guys are part of this universe as well, because you are the ones doing basic research, which is the foundation on which all, you know, all of this is, is ultimately built. So you have universities and other research organizations. You have the funding bodies that sit behind those that decide where the research money goes. And then out the other end of the process you have ethics committees that are involved in approving clinical trials. You have payers. So these are the organizations that ultimately pay for medicinal products in the UK, for example, that's the NHS. Parmvir: Yep. David: In the US, that would be insurance companies. Parmvir: Yeah. David: You have many other stakeholders. So you have obviously healthcare professionals at the end of the day, new drugs have to be woven into the fabric of medicine. And so you have to bring HCPs along with you. There are the learning bodies as well in relation to HCPs, the kind of professional bodies.So that's really at a kind of galaxy level, these are all the different solar systems. And then within them, if you look at the pharmaceutical biotechnology and service provider solar system, within those you have an incredibly complicated set of different skills departments, functions, you have the functions that are doing discovery.So these are the early days of, development where, you know, biologists and chemists are working out, you know, what are the new therapeutic targets we can look at? Then you have the clinical development division. You have the patent divisions, you have the regulatory affairs functions. You have the pharmacovigilance functions. You have the medical affairs functions, you have the medical information functions [Parmvir cackles]. There are, and I'm going to miss out many, many. You have the, the bio stats folks, you have the medical writers. And then of course you have the manufacturing, which is in itself a completely different, you know, specialized world.So yeah, you're dealing with a very complicated process with lots of things which are interlinked. But for me, if you think of all these things, like if you use layout or different compass, let's say, and I'm talking about the compass you use to check direction, not the ones you used to draw circles [Parmvir laughs] and if you scatter them all out they'll all be pointing at different directions. You know, all of these different entities have their own priorities. Because of course the industry as a whole is developing many different medicinal products for different reasons. I think when COVID came along, it was like drawing a magnet across the top of all those compasses and it got all the needles to point in the same direction.So you had governments who had a clear incentive to try and support the development of treatments. So you had governments putting up money, which was perhaps slightly unusual. They were putting money into basic research, such as the type of stuff that you guys do. They were putting money into diagnostics, which are critical for things like COVID.They were putting money into the development of vaccines and into treatments. And then of course, you know, you have the pharma companies where there was a scramble to try and develop something, to help humanity in its hour of need. You had the regulators with a lot of focus on them you know, and everyone watching their, every move and trying to ensure that you know, as many processes that often might take months, or perhaps even years were made as efficient as possible.Parmvir: Mm-hmm David: And it was a unique point in time because everyone was lined up with the same objective. So it meant, for example, that, you know, parts of the industry, which are normally a nine to five job, became a 24/7 job. Parmvir: Yeah. David: For a short period of time.And there was a huge amount of collaboration, which happened between the different stakeholder groups, you know regulatory authorities offered perhaps free scientific advice to companies that were developing this stuff. They met very regularly with companies that were in development. They gave a lot of advice as to what their expectations were when the data was received by them. They shortened some administrative pathways let's say which usually take a lot of time. They prioritized resource. So there's resource specifically waiting for this data to come in. And so, yeah, a lot of normal processes were adapted so that things could be done as efficiently as possible.And the outcome was that, you know, these drugs went through the entire process in a much more efficient way than would usually be encountered. I think another thing as well is with things like vaccines, the side effects that we anticipate to see, including the rare unusual ones ordinarily these manifest within, you know, days or weeks.It's not something that usually we anticipate things to occur years later. So there was that aspect too, but yeah, it was a, it was a unique time. Parmvir: Yeah. And actually this is a good throwback to Dr. Carina Rodriguez's podcast because she ran one of the clinical trials for the vaccine in children at USF where I work.David: Oh, fascinating. Parmvir: Yeah, so she talked about some of the things that you mentioned as well. David: I should say I was not involved sadly in any of the COVID vaccine development, but you know, it was fascinating to watch and actually to see my profession become a talking point in the news every day. Parmvir: Yes. David: It was very interesting to see all of this play out.Parmvir: Yeah. So actually, that's probably a good point to pause and ask you, what do you actually do? David: Okay. So [everyone laughs]. So as I've kind of indicated the process of pulling in adverse event data of coding it, which is the term we use for tidying up all of the data, putting it into a safety database, writing those narratives, getting the medical review, getting the important cases out the other end to the regulators, writing the reports, doing the signal section.These are very complicated processes and every company will develop them slightly differently. You know, small biotech companies, they might only have one product. It might only be approved in one or two countries. A top five pharma company will have hundreds of products authorized in many countries around the world. But all of these processes are put together in compliance with extremely strict regulations. Regulations that as I said exist in almost every country in the world and actually the regulations kind of cross over in the sense of, if you have a product that's authorized for marketing in the UK and the US, for example you know, the UK requires you to collect all the data and analyze it as does the US.They also require you to collect the data from each other's territories so companies are in the middle of the very complicated regulatory framework, which is a little bit different in each country, but fortunately is harmonized through some international bodies and international terminology. But building pharmacovigilance systems is complicated and it has to be done right. Firstly, for the obvious reason that we want to protect patients it's in no one's interest that that that patients are not protected. But also, you know, the penalties for not complying with these complex regulatory requirements are severe. And so my job really, as a, let's say senior leader within a pharmacovigilance department is to make sure that we build the right structures.And for these companies that we that we keep an eye out on all the areas, which are potential challenges and that companies are being compliant with the legislation to which we're all held. And so, so yeah, so building pharmacovigilance systems, I think is the simplest way I can describe it.Parmvir: It sounds pretty heavy and pretty complicated. David: Yeah. I mean, if you look at the larger pharma companies, if you add up all of the resource that they put into pharmacovigilance that they're legally required to put into pharmacovigilance, to service the needs of their products. A lot of things are outsourced these days, if you the count everything that comes from the outsourcing organizations as well, the big pharma companies have thousands of people like me involved in the processing and analysis of this data. So it is a big area, and that is all we do. You know, we are not involved in any other aspect of the drug. Not involved in the sales and marketing, for example, with the product, that's almost the complete opposite side of the company to us, all we do is you know, work in this very professionalized, very standardized discipline, which is pharmacovigilance. Parmvir: So David has a couple of questions. So first one should be relatively quick, which is that, is there a regulatory authority that is the gold standard? David: [David laughs] This is a very politically sensitive one.There are certainly some regulatory authorities who, particularly in some of the larger markets who are let's say more prominent. So examples would be the US FDA, the food and drug administration that is the drug regulatory authority for the United States. In the UK, we also have an extremely prominent regulator, the MHRA they're one of the oldest regulators, I believe in the world. So that's the UK medicines and healthcare products, regulatory agency. But you know, every country has its own regulator and whilst there are some who put themselves out there, perhaps as world leading regulators, there are just as many others that are doing the same important job for their countries. The European Union and European Economic Area has a slightly more complicated system because they have a coordinating regulatory authority, which is the European Medicines agency, the EMA, who many of you all have heard about in news reports, particularly during the COVID situation. But at a national level, you also have all of the national regulators who are working in tandem with the EMA. Parmvir: Okay. So this sounds quite different from, obviously it's very different from what you were doing during your PhD. David: Yes. Parmvir: He also wants to know, how did your PhD work, prepare you to do what you do now. David: If I could sum it up in one phrase, and this is a phrase which is overused, but I think in this case, it is really true: problem solving.Parmvir: Mm-hmm David: because it's interesting, you mentioned earlier that you and I we're almost engineers. Well, I went from becoming a physical engineer, at least in a lab environment to a process engineer. And, you know, I always used to think very naively when I was doing the basic research with you, I used to think, look, we are solving problems that no one knows the answer to. This must be the hardest job in the world. [Parmvir laughs] We're not solving manmade problems. Manmade problems must be so easy to solve. But no manmade problems [Parmvir laughs] are also particularly challenging. And when I say manmade problems, you know, I'm not talking about problems that someone is deliberately created, it's just, you know, logistical challenges, and just the challenges caused by working in, you know, different regulatory envionments with different sets of requirements and how to build processes that meet all of the requirements at the same time. And react to events, of course, because it might well be that you've had a product that has been ticking along nicely for a long time. And then suddenly there is a safety concern with the product. And if that safety concern is in the public domain, you will be deluged with reports in relation to that product called stimulated reporting. And you know, of course sometimes companies will be subject to class action lawsuits particularly in the US. So they might also receive large volumes of reports all in one go. All of those reports have to meet the same legal timelines, but now suddenly you've got 10,000 reports landed on your desk. Each one takes four hours to process and they're all due to the regulators in 15 days. So yeah, it is challenging working in a hyper regulated environment. Parmvir: Essentially these are problems that come about because we are humans. David: Exactly. Yeah. Parmvir: And we have to somehow live together. David: Yeah. Parmvir: So I had a couple of questions from my little sister and these might not be directly related to your work, but they are related to the fact that you work within an environment that involves clinical trials and patients and so on.And so Sukhy wants to know are side effects from drugs, usually the same for healthy people versus patients. David: This is a great question and cause me a little bit of head scratching. I think, I mean, the answer is it depends, I think by and large. Yes. But there will be some exceptions and those exceptions include things like some of the oncology treatments, because obviously there is an interaction often between the drug and the tumor, for example, so in a healthy person you can't emulate that because there is no tumor. So an example would be a phenomenon called tumorlysis syndrome which can only occur when there's a tumor to react to the particular drug. But by and large, yes, we extrapolate safety data from healthy individuals initially, which is why the earlier phases of studies are done often in healthy volunteers with some exceptions. But yeah. Then when we move on to phase two and then phase three, phase two and three are conducted in patients that have the indication of interest, I have the disease that we're trying to treat.Parmvir: So another question she had: how do you know people who are not healthy will be able to tolerate the drugs given that initially that they're tested on healthy people?David: So the first thing I would say is I'm not an expert in the design of clinical trials, but as I said, as you go through phase one which are the trials that are normally on healthy patients, you actually start out with a tiny, tiny dose. So you have an idea of dosing from your animal studies, but the data isn't always transferrable. But you take the maximum tolerable dose in animals, including in the most sensitive animals. And you then cut that by huge factor by perhaps 500 fold. Parmvir: Right. David: So you start out with a tiny amount and then you escalate up the doses to see how the patients are tolerating the drug, not the patients subject, I should say. So these are healthy volunteers usually. Parmvir: Yep. David: So that's phase one, but yeah, then of course, when you go into phase two, you're dealing with a different patient population. I don't know exactly how that's always done, but of course, you know, trials are put together by experts in the field. And they involve, you clinicians whose expertise is this particular area of medicine.Parmvir: Yeah. David: And of course it's not just the physicians at the pharmaceutical company and the biopharma company and the scientists, I should say as well. Also, this stuff is going to regulatory authorities, it's going to ethics committees, all of whom will have their own areas of expertise. So, you know, protocols are designed around the patient and to ensure the patients are not put at unnecessary risk.Parmvir: Ah, sometimes David sends me one of those questions that really makes me giggle. And this is if regulations are so important and onerous, how do I start my own biotech in the garage? David: [David laughs] Well, it's interesting, you know, companies don't necessarily have to be that big themselves to get started, but what they will need is a lot of help.Parmvir: Yeah. David: So what you'll see these days is you know, new biotechs starting up. But they rely very heavily on outsourcing. So they will partner with service providers with contract research organizations, with contract manufacturing organizations, all sorts of other parties that have the expertise that perhaps they aren't able to pull together themselves.But yeah, there are some companies out there, particularly smaller companies in earlier development that are, you know, pretty small might have 20 people in the company. Parmvir: Yeah. David: But they will need to rely on the help of many others, because going back to the kind of universe description that I gave, you know, there are so many specialized areas that you need to have covered in order to pull together everything you need, both to run a clinical trial. and also to submit a marketing authorization application. And then also keep your product compliant with all of the legal requirements that are out there.Parmvir: It's a lot.David: It is a lot, and you know this is why drug development is so costly because it needs a truly vast number of specialists involved. And, you know, quite a lot of physicians as well. And also, you know, most drugs that enter drug development don't make it all the way through the other end, so the end costs of medicinal products also have to cover the cost of the drugs that didn't make it.And plus companies only have a certain period of exclusivity before their drug becomes generic, i.e., other companies can start making it. Parmvir: So this is purely from a personal perspective, from your point of view: what do you think about the fact that obviously you have these companies who have put so much money developing these things, which were designed to treat a global pandemic. And yet we found that for example, like entire continents, like Africa still don't have a lot of people vaccinated against COVID 19, and those companies will refuse to open up the patents to allow them to be able to get people to stay healthy. David: Yeah, it's an area that really I'm not really sufficiently qualified to talk on. And I'm not just saying that, you know, through not wanting to put my foot in my mouth, but particularly with some of the vaccine technologies that were used, they were not simple medicines to manufacture. So not simple to manufacture, not simple to store, not simple to distribute. And sometimes I guess, it is perhaps a legitimate concern of a company that if other companies start making their same drug to a lower quality, that can have ramifications elsewhere. Now I'm not saying that that was the reason behind some of what you mentioned. Now there was a vaccine that was developed the UK vaccine which was specifically developed from the outset to be made available in developing world countries, let's say, and specifically to be made available at cost. And even the way that product was designed, it can be manufactured and stored at fridge temperature Parmvir: mm-hmm, which is a big deal. David: Exactly. It is a big deal, you know, those are all very important components to consider. A vaccine that could be used in those environments. But even, I remember because I vacuumed up all of the documentaries I think on television, Netflix, everywhere else about all of the challenges that were being faced. And, you know, there were even things that you just wouldn't think about, which was, you know, because the mRNA vaccines had to be stored at -80 [degrees Celsius], there wasn't enough minus 80 freezers in the developed countries, let alone figuring out how to develop and ship these to other countries with different climatic conditions.And so you even had the manufacturers of that type of equipment, having to up their game and suddenly churn out much more equipment than they previously had. So, yeah, there's no simple answer. I mean, historically there've been other challenges in the past with other types of drugs, such as the HIV medications. In the end access to those drugs was resolved through very careful dialogue between companies, regulators others. Access issues, I believe to those drugs, and again, this is just basically what I see on documentaries and other things; where are access problems these days, they're not in relation to the drug supply chain they're in relation to other things like people not wanting to come forward and receive treatment because of the stigma associated with things like that.Parmvir: So in short, do you enjoy your work? David: I do. I mean, I can honestly say that in my work every day is different. I'm very privileged in my job to support a number of different companies that are developing different products with a very wide variety of indications. And also, you know, just when you think you've seen it all worked with a wide variety of medicinal products, suddenly something completely new will come along. For example, we are now on the precipice of many commercial gene therapies coming out. Parmvir: Ooh. David: And you know, those products have some different considerations. Perhaps some of these interventions are irreversible Parmvir: mm-hmm.David: So, you know, what happens if patients do start developing something rare and unexpected. You have patients surviving a lot longer than was originally envisaged so, you know, are there other things which come about you know, as a result of the underlying disease that just no one had ever seen before. And yeah, many other types of technologies and the regulations are always having to evolve to take into account of these new therapies and the challenges associated with them.Parmvir: Well, it sounds like you will continue to live in interesting times. David: Yeah. I don't think I'm going anywhere anytime soon . Parmvir: Well, thank you so much for your time today, David. That was fantastic. And yeah, as I say, we kind of thought of you as soon as we started thinking about the safety surrounding things like COVID vaccines and knew that was your jam.So yes, we very much appreciate your time today. David: Okay. Thank you very much. [musical interlude]David: So I mentioned earlier that at an early point in my PhD, I switched to studying vascular endothelial cells that were harvested from pigs. So essentially these were pigs that were being slaughtered for the meat industry. And so I had to look through a phone book and identify an abattoir that I could go to and get the tissue that I needed to do my experiments so obviously this all had to start somewhere. So I put in a call to an abattoir in deepest, darkest Essex. And I gingerly made my way on the train to this place, which of course was in the middle of rural nowhere. And unfortunately the first day that I picked to go, it was snowing. Now we don't get vast amounts of snow in Southern England, but this was a decent sprinkling of snow. So I arrived in this quiet rural destination and I walked across various fields. I think I'd perhaps just got GPS on my phone, but it was very early days. And I was lost in fields of white in no time at all. So I ended up putting in a call to, the guys, to, come and pick me up, which they very kindly did. So then, you know, at that time I really didn't know what a coronary artery looked like so what I decided to do for that first trip was I just collected the fresh hearts that they were able to bring out the processing facility. So these were kind of warm pig hearts, freshly harvested from animals. I think I had three hearts or something like that. And so I had a large polystyrene box with me with some ice in it. And I think they were kind enough to give me the ice, as I put these hearts inside bags and put them in the box and then started making my way back to London. And of course, you know, this being a cold day, the heating was on, on the train, and so as I was sat on the train, in fact, I think it was when I got onto the tube, I suddenly became horrified that my polystyrene box was starting to leak water. And of course I knew, but no one else knew on the tube that within that water were bags, perhaps not secured, very tightly containing hearts and containing probably a fair amount of blood.And I suddenly started sweating that this puddle that was starting to pull around my polystyrene box on the floor of the tube would suddenly start to go pink and then red. And then before I knew it, I would be in serious trouble. So it was just one of those situations where the tube journey seemed to get longer and longer, and I was sweating more and more and then it got to the point where I felt that I couldn't wait any longer, so I kind of dashed outta the tube at the next station went up what was perhaps one of the longest escalators on the underground and managed to just get out the other side before I caused perhaps a fake terrorist incident or something like that. I was trying to think about how I would explain that I'd got three hearts in my polystyrene box and a set of scalpels bearing in mind that pig's hearts are very similar size to human hearts as well. So, yes, I managed just about to get to the lab. I clearly looked quite distressed, I suppose when I got back to the lab. So I started telling this story to my PhD supervisor, Dennis, and uh a retired professor that had come into the department, Don. And before too long, the two of them were crying with laughter at my story.So, um, so yeah, so that was my very first trip and yes, never, never forgotten.[musical outro]David: Our lab, when we first joined, it was quite old and a bit dog eared. And there was one particular chair in the office, which was, I mean, it was like a typical office swivel chair, but it had definitely seen better days and it was extremely uncomfortable. And when we had lab meetings, no one wanted to sit on this chair. And so Parmvir and I nicknamed it, Beelzebub's stool.
Jimbo is joined by Carl Anka, Matt Davies-Adams and Flo Lloyd-Hughes after a huge weekend of FA Cup shocks and the AFCON final.Non-league Boreham Wood beat Bournemouth to reach round 5. Kidderminster almost join them but are overcome by Declan Rice FC.Nottingham Forest thrash the holders Leicester. But are they chasing a pointless dream and should promotion to the Premier League be the real goal? And will Cooper, Johnson and Spence be there next season?Man United are knocked out by Middlesbrough on penalties. Are the hungry fans watching Rangnick's good plan executed in a mediocre fashion?Senegal and Sadio Mane finally shed the weight of previous failures by winning their first ever AFCON title. Maher Mezahi has more from Cameroon.Plus tiny tables, Chris Hughton and the pass of the season.RUNNING ORDER: • PART 1a: Boreham Wood through, Kidderminster almost (03m 00s)• PART 1b: Nottingham Forest 4-1 Leicester (10m 00s) • PART 2a: Middlesbrough knock out Man United (21m 00s) • PART 2b: Other FA Cup highlights (31m 00s)• PART 3a: Senegal win AFCON with Maher Mezahi (35m 00s)• PART 3b: Chris Hughton to become Ghana manager (48m 00s)• PART 4: EFL, WSL and the PL week to come (55m 00s)SIGN UP TO THE ATHLETIC TODAY FOR 33% OFF THE PRICE OF AN ANNUAL SUBSCRIPTION• theathletic.com/totallyGET IN TOUCH:• follow us on Instagram• find us on Facebook• send us a tweet: @TheTotallyShow READ STUFF ON OUR WEBSITE:• check out thetotallyfootballshow.com. Hosted on Acast. See acast.com/privacy for more information.
© 2020-2025 Ivy Podcast Discovery LLC
